Company

Johnson & Johnson

Johnson & Johnson has 36 drugs tracked on RxWires: 3 post-market, 7 approved, 11 in Phase 3, 5 in Phase 2, 8 in Phase 1.

Pipeline

Drug	Phase	Indication
Teclistamab	Post-Market	Multiple Myeloma
Daratumumab	Post-Market	Multiple Myeloma
Paliperidone ER	Post-Market	Schizophrenia
TOLECTIN DS	Approved
LEVAQUIN	Approved
SIRTURO	Approved
INVOKANA	Approved
XARELTO	Approved
IMODIUM MULTI-SYMPTOM RELIEF	Approved
TALVEY	Approved
Acetaminophen/Naproxen Sodium Fixed Combination	Phase 3	Pain
JNJ-90301900 (NBTXR3)	Phase 3	Carcinoma, Squamous Cell
Milvexian	Phase 3	Atrial Fibrillation
Epoetin alfa	Phase 3	Anemia
Pegylated liposomal doxorubicin	Phase 3	Metastatic Breast Cancer
acetaminophen	Phase 3	Osteoarthritis, Hip
Ribavirin	Phase 3	Genotype 1 Chronic Hepatitis C
Benzocaine 8 mg	Phase 3	Sore Throat
Mebendazole	Phase 3	Healthy Volunteers
Topiramate	Phase 3	Bipolar Disorder
CG 5503;tapentadol	Phase 3	Osteoarthritis
PROCRIT	Phase 2	Anemia
JNJ-18038683	Phase 2	Major Depressive Disorder
JNJ-26489112	Phase 2	Photosensitive Epilepsy
Nepicastat	Phase 2	Posttraumatic Stress Disorder
Azacitidine	Phase 2	Myelodysplastic Syndromes
JNJ-1761981	Phase 1	Neoplasms
JNJ-87704916	Phase 1	Neoplasms
JNJ-86974680	Phase 1	Carcinoma, Non-small-Cell Lung
JNJ-31001074	Phase 1	Pharmacokinetics
JNJ-41443532	Phase 1	Healthy
14C-paliperidone	Phase 1	Schizophrenia
ivermectin	Phase 1	Healthy
A:JNJ-39758979/Placebo #1	Phase 1	Histamine Induced Itch
6 mg Experimental nicotine gum	Not Applicable	Tobacco Dependence
Group 1	Not Applicable	Adult Skin Healthy Signs

Follow Johnson & Johnson on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.

Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.